These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1039 related items for PubMed ID: 29935970

  • 1. 68Ga-PSMA PET/CT in Patients with Rising Prostatic-Specific Antigen After Definitive Treatment of Prostate Cancer: Detection Efficacy and Diagnostic accuracy.
    Hamed MAG, Basha MAA, Ahmed H, Obaya AA, Afifi AHM, Abdelbary EH.
    Acad Radiol; 2019 Apr; 26(4):450-460. PubMed ID: 29935970
    [Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Apr; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of Gallium-68 prostate-specific membrane antigen, positron emission tomography/computed tomography (GA-68 PSMA PET/CT) in recurrent prostate cancer: a retrospective review of initial clinical experience at Tygerberg Hospital.
    Sangiwa BA, Burger C, Ellmann A.
    Pan Afr Med J; 2024 Apr; 48():30. PubMed ID: 39220559
    [Abstract] [Full Text] [Related]

  • 4. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

  • 5. Detection Efficacy of Hybrid 68Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria.
    Einspieler I, Rauscher I, Düwel C, Krönke M, Rischpler C, Habl G, Dewes S, Ott A, Wester HJ, Schwaiger M, Maurer T, Eiber M.
    J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
    [Abstract] [Full Text] [Related]

  • 6. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.
    Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, Scarpa L, di Santo G, Roig LG, Maffey-Steffan J, Horninger W, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
    [Abstract] [Full Text] [Related]

  • 7. 68Ga-labelled PSMA ligand HBED-CC PET/CT imaging in patients with recurrent prostate cancer.
    Akdemir EN, Tuncel M, Akyol F, Bilen CY, Baydar DE, Karabulut E, Ozen H, Caglar M.
    World J Urol; 2019 May; 37(5):813-821. PubMed ID: 30151600
    [Abstract] [Full Text] [Related]

  • 8. Multiphasic 68Ga-PSMA PET/CT in the Detection of Early Recurrence in Prostate Cancer Patients with a PSA Level of Less Than 1 ng/mL: A Prospective Study of 135 Patients.
    Beheshti M, Manafi-Farid R, Geinitz H, Vali R, Loidl W, Mottaghy FM, Langsteger W.
    J Nucl Med; 2020 Oct; 61(10):1484-1490. PubMed ID: 32060214
    [Abstract] [Full Text] [Related]

  • 9. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy.
    Rauscher I, Düwel C, Haller B, Rischpler C, Heck MM, Gschwend JE, Schwaiger M, Maurer T, Eiber M.
    Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
    [Abstract] [Full Text] [Related]

  • 10. 68Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer: diagnostic sensitivity and interobserver agreement.
    Basha MAA, Hamed MAG, Hussein O, El-Diasty T, Abdelkhalek YI, Hussein YO, Alasamer AF, Mohamed HAE, Deen DSE, Tantawy EF, Metwally MI, Zaitoun MMA, Aly SA, Altohamy JI, Mohamed AEM, Afifi AHM, Harb O.
    Abdom Radiol (NY); 2019 Jul; 44(7):2545-2556. PubMed ID: 30963182
    [Abstract] [Full Text] [Related]

  • 11. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
    Kabasakal L, Demirci E, Nematyazar J, Akyel R, Razavi B, Ocak M, Aygun A, Obek C, Kural AR.
    Nucl Med Commun; 2017 Feb; 38(2):149-155. PubMed ID: 27893589
    [Abstract] [Full Text] [Related]

  • 12. Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach.
    Albisinni S, Artigas C, Aoun F, Biaou I, Grosman J, Gil T, Hawaux E, Limani K, Otte FX, Peltier A, Sideris S, Sirtaine N, Flamen P, van Velthoven R.
    BJU Int; 2017 Aug; 120(2):197-203. PubMed ID: 27981732
    [Abstract] [Full Text] [Related]

  • 13. Preliminary results of a 68 Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making.
    Rousseau C, Le Thiec M, Ferrer L, Rusu D, Rauscher A, Maucherat B, Frindel M, Baumgartner P, Fleury V, Denis A, Morel A, Varmenot N, Debeaupuis E, Campion L, Kraeber-Bodéré F.
    Prostate; 2019 Sep; 79(13):1514-1522. PubMed ID: 31421657
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Detection efficacy of [89Zr]Zr-PSMA-617 PET/CT in [68Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer.
    Rosar F, Khreish F, Marlowe RJ, Schaefer-Schuler A, Burgard C, Maus S, Petto S, Bartholomä M, Ezziddin S.
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2899-2909. PubMed ID: 37148297
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. 68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.
    Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, Fanti S.
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):31-39. PubMed ID: 30350010
    [Abstract] [Full Text] [Related]

  • 18. 3-Year Freedom from Progression After 68Ga-PSMA PET/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial.
    Emmett L, Tang R, Nandurkar R, Hruby G, Roach P, Watts JA, Cusick T, Kneebone A, Ho B, Chan L, van Leeuwen PJ, Scheltema MJ, Nguyen A, Yin C, Scott A, Tang C, McCarthy M, Fullard K, Roberts M, Francis R, Stricker P.
    J Nucl Med; 2020 Jun; 61(6):866-872. PubMed ID: 31676727
    [Abstract] [Full Text] [Related]

  • 19. Enhancing PSMA-uptake with androgen deprivation therapy - a new way to detect prostate cancer metastases?
    Leitsmann C, Thelen P, Schmid M, Meller J, Sahlmann CO, Meller B, Trojan L, Strauss A.
    Int Braz J Urol; 2019 Jun; 45(3):459-467. PubMed ID: 30901173
    [Abstract] [Full Text] [Related]

  • 20. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
    Schmidkonz C, Cordes M, Goetz TI, Prante O, Kuwert T, Ritt P, Uder M, Wullich B, Goebell P, Bäuerle T.
    Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.